2021
DOI: 10.1007/s00403-021-02262-7
|View full text |Cite
|
Sign up to set email alerts
|

Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 79 publications
0
6
0
Order By: Relevance
“…2,3 Ustekinumab has been used in children suffering from inflammatory bowel disease and CARD14-associated papulosquamous eruption (CAPE). 4 We present the use of an anti-interleukin 12/23 monoclonal antibody therapy in combination with acitretin for the effective treatment of pediatric PRP. In line with other anecdotal reports, ustekinumab proved effective and tolerable in the treatment of refractory PRP.…”
Section: Discussionmentioning
confidence: 99%
“…2,3 Ustekinumab has been used in children suffering from inflammatory bowel disease and CARD14-associated papulosquamous eruption (CAPE). 4 We present the use of an anti-interleukin 12/23 monoclonal antibody therapy in combination with acitretin for the effective treatment of pediatric PRP. In line with other anecdotal reports, ustekinumab proved effective and tolerable in the treatment of refractory PRP.…”
Section: Discussionmentioning
confidence: 99%
“…Here we report on the efficacy and safety of ustekinumab in three patients with NS. Ustekinumab is a monoclonal antibody targeting the p40 subunit of IL‐12 and IL‐23 which has been shown to be highly effective in psoriasis, psoriatic arthritis and other inflammatory skin diseases 21 . The rationale for targeting the IL‐23/IL‐17 axis in NS stems from a previous report showing IL‐17 skewing in ichthyosis patients and NS in particular 12 .…”
Section: Discussionmentioning
confidence: 99%
“…Ustekinumab is a monoclonal antibody targeting the p40 subunit of IL-12 and IL-23 which has been shown to be highly effective in psoriasis, psoriatic arthritis and other inflammatory skin diseases. 21 The rationale for targeting the IL-23/IL-17 axis in NS stems from a previous report showing IL-17 skewing in ichthyosis patients and NS in particular. 12 Moreover, NS patients demonstrate high levels of IL-19, which is induced by both Th17 and Th2 cytokines and in turn amplifies IL-17 effects in keratinocytes.…”
Section: Con Clus Ionsmentioning
confidence: 99%
“…Aside from these labeled indications, ustekinumab has been used "off-label" for other inflammatory diseases. 6 However, while multiple publications, mainly case reports and a small number of case series, have shown excellent results of ustekinumab when prescribed off-label for treatment of various skin conditions, there is a lack of a systemic reviews in the literature. Hence, in this review we discuss ustekinumab's pharmacological effects, efficacy, and safety in the treatment of psoriasis.…”
Section: Introductionmentioning
confidence: 99%